Clinical trials: HER2 + Gastric Cancer
Gastric Cancer, Gastrointestinal Cancer
Neratinib and Fam-Trastuzumab Deruxtecan in Advanced Gastro-esophageal Cancer Patients
This is Phase 1 dose finding trial with potential dose expansion to evaluate the safety, toxicity, recommended phase 2 dose (RP2D), and maximum tolerated dose (MTD) of Neratinib plus TDxD using a standard 3+3 dose escalation…
- Conditions
- Gastric Cancer, Gastrointestinal Cancer, HER2 Gene Mutation
- Trial name
- NCT05274048
- Testing
- Neratinib Pill, Fam-Trastuzumab Deruxtecan-Nxki (TDxD)
- Where
- 3 sites in United States
- Volunteers
- 18 people
- Sponsor
- Fox Chase Cancer Center
Metastatic, Gastric or Gastro-oesophageal Junction, Cancer
Assess the Efficacy of AZD8931 in Combination With Paclitaxel Versus Paclitaxel Alone in Patients With Gastric Cancer
The purpose of the study is to assess the efficacy and safety and PK of AZD8931 plus paclitaxel versus paclitaxel alone in patients with metastatic, gastric or gastro-oesophageal junction, cancer.
- Trial name
- NCT01579578
- Testing
- AZD8931, Paclitaxel
- Where
- 15 sites in Germany, Japan and 3 more
- Volunteers
- 39 people
- Sponsor
- AstraZeneca
Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma.
The purpose of this study is to evaluate the efficacy and safety of perioperative Disitamab Vedotin plus Toripalimab and XELOX versus Disitamab Vedotin plus Toripalimab versus XELOX in subjects with HER2-expressing resectable…
- Trial name
- NCT06155383
- Testing
- Capecitabine, oxaliplatin, Disitamab Vedotin
- Where
- 11 sites in China
- Volunteers
- 90 people
- Sponsor
- RemeGen Co., Ltd.
Gastric Cancer
A Study of RC48-ADC Combination Therapies as First-line Treatment in Advanced Metastatic Gastric Cancer
This is a Phase II/III, randomized, multicenter, open-label clinical trial designed to evaluate safety and efficacy of RC48-ADC combine with Toripalimab and chemotherapy or RC48-ADC combine with Toripalimab and Trastuzumab as…
- Trial name
- NCT05980481
- Testing
- RC48-ADC（2.5mg/kg）, Trastuzumab, Toripalimab
- Where
- China
- Volunteers
- 201 people
- Sponsor
- RemeGen Co., Ltd.
Breast Cancer, Gastric Cancer
Trial of KN026 in Patients With HER2-positive Advanced Malignant Breast Cancer and Gastric Cancer
This is a first-in-human (FIH), open-label, phase 1 dose-escalation study of KN026 in subjects with HER2 positive advanced breast and Gastric Cancer. The standard "3 + 3" design was used for dose escalation.
- Trial name
- NCT03619681
- Testing
- KN026
- Where
- China
- Volunteers
- 63 people
- Sponsor
- Jiangsu Alphamab Biopharmaceuticals Co., Ltd
HER2-Positive Solid Tumor
Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid Tumor
This first-in-human study will be counducted to evaluate the safety, tolerability, pharmacokinetics (PK) and anti-tumor activity of YH32367 in Patients with HER2-Positive Locally Advanced or Metastatic Solid Tumors.
- Trial name
- NCT05523947
- Testing
- YH32367
- Where
- 19 sites in United States, Australia and 1 more
- Volunteers
- 147 people
- Sponsor
- Yuhan Corporation
Gastric Cancer
Conversion Therapy With RC48, Sintilimab, and SOX for HER2 1+/2+ Unresectable Gastric Cancer
This study aims to evaluate the efficacy of disitamab vedotin in combination with sintilimab and SOX as conversion therapy in patients with initially unresectable locally advanced or metastatic gastric cancer exhibiting HER2 IHC…
- Trial name
- Remission (NCT07194005)
- Testing
- Disitamab vedotin(RC48), Sintilimab, S-1
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Fudan University
Gastric Cancer, Gastroesophageal Junction Cancer
Human Epidermal Growth Factor Receptor 2 (HER-2) Status in Gastric and Gastro-Esophageal Junction (GEJ) Carcinoma
The primary objective is to evaluate the concordance between human epidermal growth factor receptor 2 (HER2) status determined by the participating laboratory and by the centralized laboratory.
- Trial name
- NCT02731313
- Testing
- Trastuzumab
- Where
- 19 sites in France
- Volunteers
- 420 people
- Sponsor
- Hoffmann-La Roche
Locally Advanced Gastric Cancer, Metastatic HER2 Positive Gastroesophageal Junction Cancer
A Study of MRG002 in the Treatment of HER2-positive/HER2-low Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Cancer.
The objective of this study is to assess the safety, efficacy, pharmacokinetics, and immunogenicity of MRG002 as single agent in patients with HER2-positive /HER2-low locally advanced or metastatic gastric/ gastroesophageal…
- Trial name
- NCT05141747
- Testing
- MRG002
- Where
- 3 sites in China
- Volunteers
- 60 people
- Sponsor
- Shanghai Miracogen Inc.
Gastric or Gastroesophageal Junction(GEJ) Adenocarcinoma
A Study of Trastuzumab in Combination With Capecitabine and Cisplatin in Patients With Tissue HER2- But Serum HER2+ AGC
A phase II clinical study of trastuzumab in combination with capecitabine and cisplatin (XP) in patients with tissue HER2-negative but serum HER2-positive advanced gastric cancer
- Trial name
- NCT04309578
- Testing
- Trastuzumab, Capecitabine and Cisplatin
- Where
- South Korea
- Volunteers
- 28 people
- Sponsor
- Asan Medical Center
HER-2 Positive Gastric Cancer, Metastatic Cancer
Herzuma-capecitabine/Cisplatin for Gastric Cancer
Stomach cancer is the fifth largest cancer in the world. Despite many combinations of studies, metastatic stomach cancer shows a median survival period of 10 to 12 months.
- Trial name
- HERZUMA-GC (NCT03588533)
- Testing
- Trastuzumab, Capecitabine, Cisplatin
- Where
- South Korea
- Volunteers
- 50 people
- Sponsor
- Sung Yong Oh
Stomach Neoplasms
Investigation of the Proportion of Human Epidermal Growth Factor Receptor 2 Protein Overexpression of Gastric Adenocarcinoma and Prognostic Effect of HER2, and Analysis of Practice Pattern of Herceptin Use in Stage IV Gastric Cancer
The objective of this study is to investigate the proportion of HER2 overexpression in gastric cancer patients group, to evaluate the relation of HER2 overexpression with prognosis, and to analyze the proportion of herceptin…
- Trial name
- HER2 (NCT02136836)
- Where
- South Korea
- Volunteers
- 860 people
- Sponsor
- Yonsei University
Gastric Cancer
A Study of Nivolumab Plus Chemotherapy in First Line Treatment of Adult Participants With Advanced or Metastatic Gastric Cancer
The purpose of this observational study is to assess the effectiveness and safety of nivolumab in participants with previously untreated advanced or metastatic Gastric Cancer (GC), Gastro-oesophageal Junction (GEJ)…
- Trial name
- INGA (NCT05165264)
- Where
- Germany
- Volunteers
- 600 people
- Sponsor
- Bristol-Myers Squibb
Gastric Carcinoma
A Study of Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus Chemotherapy Combined With Trastuzumab With or Without Pembrolizumab in HER2-high Expression Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.
The purpose of this study is to evaluate the efficacy and safety of Disitamab Vedotin combined with Trastuzumab and Tislelizumab Versus Chemotherapy Combined with Trastuzumab with or without Pembrolizumab as First-Line Treatment…
- Trial name
- NCT07315750
- Testing
- Disitamab Vedotin, Tislelizumab, CAPOX (oxaliplatin/capecitabine)
- Where
- China
- Volunteers
- 555 people
- Sponsor
- RemeGen Co., Ltd.
Gastric Cancer
Efficacy and Safety of Disitamab Vedotin Combined With Sintilimab
Efficacy and Safety of Disitamab Vedotin Combined With Sintilimab in Second-line Treatment of Advanced Gastric Cancer: a Prospective, Single Arm Clinical Study
- Trial name
- NCT05928897
- Testing
- Disitamab Vedotin combined with Sintilimab
- Volunteers
- 30 people
- Sponsor
- Xiangya Hospital of Central South University
Acute Myeloid Leukemia, Brain Glioblastoma
Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer
This randomized pilot clinical trial studies health care coach support in reducing acute care use and cost in patients with cancer.
- Conditions
- Acute Myeloid Leukemia, Brain Glioblastoma, Estrogen Receptor Negative, Extensive Stage Small Cell Lung Carcinoma
- Trial name
- NCT03154190
- Testing
- Best Practice, Laboratory Biomarker Analysis, Supportive Care
- Where
- United States
- Volunteers
- 128 people
- Sponsor
- Stanford University
Gastric Cancer, Chemotherapy
A Study to Evaluate the Efficacy and Safety of Sintilimab Plus Apatinib and Chemotherapy in Patients With HER-2 Negative Microsatellite Stability (MSS) Advanced or Metastatic Gastric (GC) or Gastroesophageal Junction (GEJ) Cancer
To evaluate the efficacy and safety of Sintilimab combined with apatinib and chemotherapy as First-line or second-line Therapy in Treatment of HER-2 negative MSS Advanced or Metastatic GC or GEJ Cancer.
- Conditions
- Gastric Cancer, Chemotherapy, Immunotherapy
- Trial name
- NCT05216237
- Testing
- Sintilimab 200 mg, intravenously (IV) every 3 weeks(Q3W)
- Where
- China
- Volunteers
- 31 people
- Sponsor
- Jiuda Zhao
HER2-positive Breast Cancer, HER2-positive Gastric Cancer
BI-1607 in Combination with Trastuzumab in Subjects with HER2-positive Advanced Solid Tumors
HER2+ breast and gastric cancer patients' survival is significantly improved by trastuzumab alone or in combination with chemotherapy.
- Conditions
- HER2-positive Breast Cancer, HER2-positive Gastric Cancer, HER2-positive Metastatic Breast Cancer, Metastatic Gastroesophageal Junction Adenocarcinoma
- Trial name
- CONTRAST (NCT05555251)
- Testing
- BI-1607, Trastuzumab
- Where
- 6 sites in Germany, Spain and 1 more
- Volunteers
- 18 people
- Sponsor
- BioInvent International AB
Breast Cancer, Gastric Cancer (GC)
PET Image Exploration of 89Zr-labeled Antibody Fragments Targeting HER2 in Patients With Malignant Tumors
The purpose of this study is to develop and clinically evaluate 89Zr-labeled HER2-targeted antibody fragments in diagnosis and screening of HER2-positive cancer patients.
- Conditions
- Breast Cancer, Gastric Cancer (GC), Urothelial Carcinoma (UC)
- Trial name
- NCT07023848
- Testing
- 89Zr-LNCab104, 89Zr-LNCab103, 18F-FDG
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Affiliated Hospital of Jiangnan University
Gastric (Stomach) Cancer
Clinical Efficacy of Pucotenlimab Combined With Lenvatinib and SOX Versus SOX Alone in Patients With HER2-Negative Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
The purpose of this study is to evaluate the objective response rate (ORR) of Pembrolizumab combined with Lenvatinib and SOX compared with SOX alone in the treatment of patients with HER2-negative advanced gastric or…
- Trial name
- FUGES032 (NCT07356466)
- Testing
- Pucotenlimab Combined with Lenvatinib, Oxaliplatin plus S-1 regimen
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Fujian Medical University